AptarGroup reports Q1 EPS $1.26, consensus $1.15

Reports Q1 revenue $915.4M, consensus $890.3M. “We are off to a great start for the year. Strong sales growth in our Pharma business and continued margin expansion in our Beauty and Closures businesses helped us achieve double-digit earnings per share growth over the prior year quarter. Our Pharma segment continued to see healthy market demand and our proprietary drug delivery systems continued to show robust growth after growing more than 30% in the prior year quarter. Additionally, North America showed positive momentum across all three segments. Our teams remain focused on cost management and improved operational leverage, and were able to decrease selling, general and administrative expenses as a percentage of sales over the prior year quarter,” said Stephan B. Tanda, Aptar President and CEO.